Pfizer names Albert Bourla as group president as Amy Schulman steps down

Changes in Pfizer’s (NYSE: PFE) executive leadership have been announced this week.

The US drugmaker announced that Amy Schulman and Pfizer have agreed to separate. As a result of that mutual agreement, Ms Schulman will not be assuming the role of Group President of Vaccines, Oncology and Consumer Healthcare and is stepping down from the company's executive leadership team, including as General Counsel and Business Unit Lead for the Consumer Healthcare business unit. She will remain at the company for a transition period.  The company said in a statement: “We thank Amy for the past five years of hard work and many contributions, and we wish her well in her future endeavors.”

Pfizer has named Albert Bourla as Group President of the Vaccines, Oncology and Consumer Healthcare business effective January 1. Ian Read, Pfizer chairman and chief executive, said: “Albert has 20 years of experience at Pfizer and has held senior global positions across a range of markets and disciplines within the company. He has a track record for delivering solid business results and most recently has been responsible for building a strong post-patent business.”